Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04189081 · ClinicalTrials.gov registry record · NA
Improvement of Dry Mouth Sufferers After Using an Experimental Dry Mouth Rinse Compared to a Water Control
A NA study of Dry Mouth, sponsored by Procter and Gamble.
- Completed
- Registry status
- NA
- Development phase
- 137
- Enrollment target
- 1
- Study location
NCT04189081: Completed NA study of Dry Mouth, sponsored by Procter and Gamble.
NCT04189081 is a NA study of Dry Mouth that has completed, run by Procter and Gamble. The registered enrollment target is 137 participants, below the 328-participant average among 3 other Dry Mouth trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04189081, a NA study of Dry Mouth, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- NA
- Development phase
- 137 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate dry mouth relief in subjects with self-reported feeling of dry mouth after using an experimental mouth rinse or a positive control compared to a water control.
Primary Outcome
Product Performance and Attributes (PPAQ I) Since you have been using the product, please rate each of the following at this timepoint: (Select one response for attribute)- excellent=5, very good=4, good=3, fair=2, poor=1: 1\) Relieves the discomfort of your dry mouth
Conditions Studied
Interventions
- DEVICE dry mouth rinse
- OTHER Water Control
Study Locations (1)
Indiana
- Salus Research - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2020-05-13 |
| Est. Completion | 2020-07-08 |
| Phase | NA |
What the finished NCT04189081 record still lists
NCT04189081 is an interventional study that assigns participants to a tested intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, below the 328-participant average among 3 other Dry Mouth trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Dry Mouth appearing as the primary indexed condition, and to 2 interventions - of which dry mouth rinse is the first listed.
NCT04189081 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT04189081 about?
NCT04189081 is a clinical study titled "Improvement of Dry Mouth Sufferers After Using an Experimental Dry Mouth Rinse Compared to a Water Control". The objective of this study is to evaluate dry mouth relief in subjects with self-reported feeling of dry mouth after using an experimental mouth rinse or a positive control compared to a water control.
What is the current status of trial NCT04189081?
This trial is currently completed. It is a NA study. The enrollment target is 137 participants. The study started on 2020-05-13. Estimated completion is 2020-07-08.
What conditions does trial NCT04189081 study?
This clinical trial studies the following conditions: Dry Mouth.
What interventions are being tested in trial NCT04189081?
The interventions under investigation include: dry mouth rinse (DEVICE), Water Control (OTHER).
Who is sponsoring clinical trial NCT04189081?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04189081 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Mouth
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI